PetMed Express (NASDAQ:PETS) Releases Earnings Results, Misses Estimates By $0.01 EPS

PetMed Express (NASDAQ:PETS) released its earnings results on Tuesday. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.01), FiscalAI reports. PetMed Express had a negative net margin of 35.51% and a negative return on equity of 70.81%. The company had revenue of $42.82 million for the quarter, compared to analyst estimates of $52.00 million.

PetMed Express Stock Down 1.9%

PETS traded down $0.04 during trading on Tuesday, hitting $2.13. 167,206 shares of the company’s stock were exchanged, compared to its average volume of 91,789. The business’s 50 day moving average is $2.27 and its two-hundred day moving average is $2.61. PetMed Express has a fifty-two week low of $1.57 and a fifty-two week high of $4.32. The stock has a market cap of $45.54 million, a P/E ratio of -0.70 and a beta of 0.77.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Occudo Quantitative Strategies LP bought a new stake in shares of PetMed Express in the 2nd quarter worth $51,000. Oxford Asset Management LLP bought a new position in PetMed Express during the second quarter valued at about $55,000. CIBC Private Wealth Group LLC bought a new position in PetMed Express during the third quarter valued at about $75,000. Jain Global LLC bought a new position in PetMed Express during the fourth quarter valued at about $78,000. Finally, Bridgeway Capital Management LLC grew its position in PetMed Express by 96.2% during the second quarter. Bridgeway Capital Management LLC now owns 40,800 shares of the company’s stock valued at $135,000 after buying an additional 20,000 shares during the period. Institutional investors and hedge funds own 73.33% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on PETS shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of PetMed Express in a research report on Tuesday, May 12th. Zacks Research upgraded shares of PetMed Express to a “hold” rating in a research report on Thursday, April 30th. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, PetMed Express currently has an average rating of “Reduce”.

About PetMed Express

PetMed Express, Inc operates as an online and catalog-based pet pharmacy and retail supplier under the 1-800-PetMeds brand name. The company distributes prescription and non‐prescription medications, nutritional supplements, flea and tick control products, and a range of pet health supplies directly to consumers. Through its licensed veterinary pharmacy in Delray Beach, Florida, PetMed Express fills orders for dogs, cats and other companion animals, offering both branded and generic products alongside its own private‐label formulations.

Founded in 1996 by Marc Puleo, PetMed Express built its business on the premise of convenience and cost savings for pet owners seeking reliable access to veterinary medications.